Seattle-based Callio Therapeutics announced a $187 million Series A on March 3, 2025, as it launched to develop multi-payload antibody-drug conjugates (ADCs) for cancer. Frazier Life Sciences led the financing. The company said it would use the proceeds to advance its HER2-targeted lead program toward clinical proof of concept and support a second ADC program.
Who led Callio Therapeutics’ $187 million Series A?
Frazier Life Sciences led the $187.0 million round, announced alongside Callio’s launch on March 3, 2025. Jeito Capital made a significant investment; Novo Holdings, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI also participated. The amount is the announced financing, not a newly reported 2026 raise. Callio’s launch announcement also said the proceeds would advance a HER2-targeted ADC and a second program that was undisclosed at the time.
What is Callio Therapeutics?
Callio is a biotechnology company developing cancer medicines called antibody-drug conjugates. At launch, it described itself as headquartered in Seattle and Singapore; its current website lists offices in Seattle, San Diego and Singapore. The company licensed its oncology multi-payload ADC platform, related intellectual property and pipeline assets through an exclusive worldwide agreement with Singapore-based Hummingbird Bioscience. The agreement included equity, potential milestone payments and royalties as consideration.
What is a dual-payload ADC?
An ADC links an antibody that recognizes a cell-associated marker to cytotoxic drug payloads, with the aim of delivering the drugs to cells bearing that marker. A typical single-payload design carries one drug; Callio’s approach combines two payloads in one targeted medicine. The company’s rationale is that combining payloads could help address resistance that can arise with existing ADCs.
#1 Best Overall
- 【FILTER IN SECONDS】Filtration can be a pain, taking hours using gravity alone. Our lab vacuum pump, which works at 10L/min, can accomplish the same job in seconds - even with highly viscous liquids. The vacuum pump can save hours in the lab and let you run more experiments - or produce more product. Many of our customers use our lab filtration pump for essential oils, e-juice, home-brewing and more
- 【OIL FREE】Many other pumps need their oil changed after only 12 hours of use. And cheaper models are also notoriously weak and unreliable. The LABFISH vacuum pump uses a powerful, 0.075Mpa oilless small diaphragm pump, which means it isn’t messy and doesn’t need regular maintenance. The pump can pull a vacuum strong enough for most lab or industrial work
- 【ANTI-SLIP】The unique base design, containing four special rubber anti-slip pads, can be steadily fixed on the workbench to prevent the machine from shaking and run more quietly and steadily
- 【COMPACT DESIGN】The small vacuum pump is compact and easy to store when not in use. It is built with sturdy lab-quality materials meant to last for years. The oilless design also guarantees that oil from the pump won’t contaminate your work - a risk in many pumps
- 【APPLICATIONS】Can be used wildly in aerator, nitrogen blower, solid phase extractor, thin layer color developing spray, solvent filter, air sampler and other vacuum pressure need.There are more uses in life. When you need to use a vacuum storage bag with a valve to store food or items, you will find it very convenient
That is a development hypothesis, not proof that the approach works better in patients. Callio co-founder and then-CEO Piers Ingram said at launch: “Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy.” The conditional wording matters: company descriptions of potential efficacy or resistance reduction are not measured clinical outcomes. The sources available do not establish that Callio’s ADCs are more effective or safer than single-payload ADCs.
What cancer treatment is Callio developing?
CLIO-8221: HER2-targeted lead program
Callio identifies CLIO-8221 as its lead clinical-stage program. It targets HER2 and combines exatecan with an ATR inhibitor. According to the company’s September 9, 2026 update, the first patient in its Phase 1 study was dosed in March 2026. Enrollment was ongoing in the United States and Australia, and Callio said it planned to open the study in China. These are company-reported trial updates; the reviewed sources do not provide an independent clinical outcome statistic for CLIO-8221. Callio’s news page lists the first-patient-dosed announcement and company scientific presentations in 2026.
Rank #2
- Ultra-Low Temperature Performance: An efficient single-stage compressor for the ultra-low temperature freezer enables fast cooling and energy saving. Temperature range from -40℉ to -123℉ provides flexible storage for sensitive lab samples
- Precise ±0.1°C Microcomputer Control: The lab freezer is microprocessor-controlled with an advanced digital interface for real-time monitoring and ultra-precise temperature adjustment, critical for preserving sensitive biological samples
- Customizable Smart Alarm System: Users can set custom temperature thresholds. Audible and visual alarms safeguard critical samples. The ultra low temp freezer includes keyed lock for physical security against unauthorized access
- Energy-saving Design: Our 25L lab cryogenic freezer features low power consumption (230W, 2.8 kWh/day), 304 stainless steel interior, premium refrigerant, and lightweight at 63.93 lbs for flexible placement
- Wide Applications: Ideal for precise scientific research, long-term sample storage, specialized material testing, and advanced biotech studies, meeting diverse lab needs
CLIO-8421 and other programs
Callio’s website lists CLIO-8421 as a TROP2 program and notes additional discovery programs without disclosing their targets. At launch, the company said it intended to fund a second ADC program but did not identify it. The current website’s program descriptions should not be read as evidence that these candidates have demonstrated clinical benefit.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Who leads Callio Therapeutics?
Callio announced Zachary Hornby’s appointment as CEO on September 9, 2026. The company said co-founder Piers Ingram moved to Senior Advisor and remained on the board. On September 28, 2026, Callio announced Chris Hassig, PhD, as Chief Scientific Officer. These leadership details reflect the company’s dated announcements.
Quick Recap
Best Value
- Ultra-Low Temperature Performance: An efficient single-stage compressor for the ultra-low temperature freezer enables fast cooling and energy saving. Temperature range from -40℉ to -123℉ provides flexible storage for sensitive lab samples
- Precise ±0.1°C Microcomputer Control: The lab freezer is microprocessor-controlled with an advanced digital interface for real-time monitoring and ultra-precise temperature adjustment, critical for preserving sensitive biological samples
- Customizable Smart Alarm System: Users can set custom temperature thresholds. Audible and visual alarms safeguard critical samples. The ultra low temp freezer includes keyed lock for physical security against unauthorized access
- Large capacity Design : Our 58L lab cryogenic freezer features premium 304 stainless steel, easy to clean. It is equipped with fast cooling single-stage compressor and all-copper refrigeration system for stable low temps
- Wide Applications: Ideal for precise scientific research, long-term sample storage, specialized material testing, and advanced biotech studies, meeting diverse lab needs
Rank #4
- High Accuracy and Precision: Each pipette is calibrated in accordance with ISO8655 and each micro pipette is supplied with an individual test certificate.
- Wide Tip Compatibility: It is compatible with most universal tip brands covering full volume range
- Humanization: ergonomic design, lightweight plunger force can reduce repetitive strain injury. The digital display can clearly read the volume setting. Tip ejector for easy and fast needle tip replacement.
- Easy to calibrate: Each pipette is fully calibrated before shipment. It's easy to calibrate for the users with the tools and instruction supplied.
- 1 Year Guarantee and Satisfied Service: we are manufacturer which has more than 20 years experience in the field of lab products. . Any quality problem, we will provide free replacement
Rank #3
- 2000 W ULTRASONIC HOMOGENIZER, 1000 to 3000 mL: A 2000 W lab ultrasonic homogenizer and cell disruptor processes 1000 to 3000 mL samples for mixing, emulsifying, homogenizing, dispersing, and particle-size reduction
- ADJUSTABLE 0 TO 100% POWER, PULSE MODE: Set ultrasonic output from 0 to 100% and use variable pulse mode to match delicate or tough samples, with automatic amplitude control for consistent results
- LCD DISPLAY, PROGRAMMABLE TIMER: A clear LCD shows all settings at a glance, with easy programming and up to 99 hours of total working-time control for hands-free, precise, repeatable ultrasonic runs
- TEMPERATURE PROTECTION, QUIET CHAMBER: A temperature indicator helps prevent overheating and a sound-abating chamber cuts cavitation noise for safe, comfortable benchtop operation
- DURABLE TITANIUM ALLOY PROBES: Engineered for longevity and biocompatibility, our high-efficiency probes are corrosion-resistant and lightweight. Perfect for cell disruption, dispersion, and emulsification in demanding lab environments
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
